Skip to search formSkip to main contentSkip to account menu

LAQ824

Known as: NVP-LAQ824 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Hydroxamic Acids

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Abstract 5277: Non-invasive metabolic biomarkers of histone deacetylase inhibition in human colon cancer cells and tumors
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Introduction: Histone deacetylase (HDAC) inhibitors are… 
2010
2010
cell death or therapeutic efficacy death receptor signaling or a functional apoptosome to mediate tumor The histone deacetylase inhibitors LAQ824 and LBH589 do not require
2009
2009
Abstract A224: Noninvasive PD markers of a pyruvate dehydrogenase kinase inhibitor, dichloroacetate, in human colon carcinoma xenografts
Pyruvate dehydrogenase (PDH) is the key mitochondrial enzyme that determines whether pyruvate formed during glycolysis from… 
2008
2008
Investigating the anti-cancer activities of the histone deacetylase inhibitors LAQ824 and LBH589
2007
2007
Effect of the histone deacetylase inhibitor LAQ824 in colon cancer cells
Colorectal cancer is one of the most cause of cancer and death in Western societies. Recently, histone deacetylase inhibitors… 
2006
2006
In vivo Biological Activity of the Histone Deacetylase Inhibitor LAQ824 Is detectable with 3¶-Deoxy-3¶-( 18 F)Fluorothymidine
Abstract Histone deacetylase inhibitors (HDACI) are emerging asgrowth inhibitory compounds that modulate gene expressionand… 
2004
2004
A combination of histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC and AML cells with constitutively active mutant FLT-3 tyrosine kinase.
6541 Background: We have reported that treatment with histone deacetylase inhibitors, LAQ824 and LBH589 (Novartis Pharma AG), and… 
2003
2003
Leukemia-Blast Crisis Cells Mesylate-sensitive or-refractory Chronic Myelogenous Bcr-Abl and Induces Apoptosis of Imatinib Expression and Promotes Proteasomal Degradation of Histone Deacetylase…
Treatment with LAQ824 (Novartis Pharmaceutical, Inc.), a cinnamyl hydroxamic acid analogue inhibitor of histone deacetylases… 
2003
2003
Effects of the hydroxamic acid histone deacetylase inhibitors trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA) and LAQ824 on histone and protein acetylation.
2002
2002
LAQ824 is a novel histone deacetylase inhibitor with significant activity against multiple myeloma: Results of a pre-clinical evaluation in vitro and in vivo.